Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Rigel Pharmaceuticals Inc RIGL

Healthcare Biotechnology
Rigel Pharmaceuticals, Inc. is a biotechnology company. The Company is engaged in developing and providing novel therapies that significantly improve the lives of patients with hematologic disorders and cancer. It is focused on products that address signaling pathways that are critical to disease mechanisms. Its first product is TAVALISSE (fostamatinib disodium hexahydrate) tablets, the... see more

Recent & Breaking News (NDAQ:RIGL)

Growing Demand for Biotechnologies are Expected to Grow

PR Newswire June 18, 2018

Rigel To Present Phase 2 Results for Fostamatinib in Autoimmune Hemolytic Anemia at EHA

PR Newswire June 12, 2018

Rigel to Present at Jefferies 2018 Global Healthcare Conference

PR Newswire May 31, 2018

Benzinga's Daily Biotech Pulse: Chinese Cheer For Gilead, Immutep Presents Positive Phase 1 Data, FDA Accepts Exelixis sNDA

Benzinga.com  May 30, 2018

Rigel Appoints Dean Schorno as Chief Financial Officer

PR Newswire May 30, 2018

Rigel Announces Availability of TAVALISSE™ (fostamatinib disodium hexahydrate) in the U.S.

PR Newswire May 29, 2018

Benzinga's Daily Biotech Pulse: SIGA Rallies On FDA Panel Backing, Rigel And Gilead React To Earnings

Benzinga.com  May 2, 2018

Rigel Announces First Quarter 2018 Financial Results and Provides Company Update

PR Newswire May 1, 2018

TAVALISSE™ (fostamatinib disodium hexahydrate) Phase 3 Data Published in the American Journal of Hematology Describes Pivotal Data and Overall Response Rate Versus Placebo

PR Newswire April 30, 2018

Rigel Announces Conference Call and Webcast to Report First Quarter 2018 Financial Results

PR Newswire April 24, 2018

Rigel Announces Pricing Of Public Offering Of Common Stock

PR Newswire April 19, 2018

Rigel Announces Proposed Public Offering Of Common Stock

PR Newswire April 18, 2018

24 Stocks Moving In Wednesday's Pre-Market Session

Benzinga.com  April 18, 2018

Rigel Announces FDA Approval of TAVALISSE™ (fostamatinib disodium hexahydrate) for Chronic Immune Thrombocytopenia (ITP) in Adult Patients

PR Newswire April 17, 2018

6 Stocks To Watch For October 4, 2017

Benzinga.com  October 4, 2017

Rigel Announces Proposed Public Offering Of Common Stock

PR Newswire October 3, 2017

Fostamatinib Meets Pre-Specified Primary Endpoint in Stage 1 of Autoimmune Hemolytic Anemia (AIHA) Phase 2 Study

PR Newswire October 3, 2017

Mid-Afternoon Market Update: Dow Gains 130 Points; CyberOptics Shares Plunge

Benzinga.com  October 2, 2017

Mid-Morning Market Update: Markets Open Higher; Cal-Maine Foods Posts Wider-Than-Expected Loss

Benzinga.com  October 2, 2017

30 Stocks Moving In Monday's Pre-Market Session

Benzinga.com  October 2, 2017